Literature DB >> 31628948

The Role of RNA in HIV-1 Vif-Mediated Degradation of APOBEC3H.

Jiayi Wang1, Jordan T Becker1, Ke Shi2, Kate V Lauer1, Daniel J Salamango1, Hideki Aihara2, Nadine M Shaban3, Reuben S Harris4.   

Abstract

As many as five members of the APOBEC3 family of DNA cytosine deaminases are capable of inhibiting HIV-1 replication by deaminating viral cDNA cytosines and interfering with reverse transcription. HIV-1 counteracts restriction with the virally encoded Vif protein, which forms a hybrid ubiquitin ligase complex that directly binds APOBEC3 enzymes and targets them for proteasomal degradation. APOBEC3H (A3H) is unique among family members by dimerization through cellular and viral duplex RNA species. RNA binding is required for localization of A3H to the cytoplasmic compartment, for efficient packaging into nascent HIV-1 particles and ultimately for effective virus restriction activity. Here we compared wild-type human A3H and RNA binding-defective mutants to ask whether RNA may be a factor in the functional interaction with HIV-1 Vif. We used structural modeling, immunoblotting, live cell imaging, and split green fluorescence protein (GFP) reconstitution approaches to assess the capability of HIV-1 Vif to promote the degradation of wild-type A3H in comparison to RNA binding-defective mutants. The results combined to show that RNA is not strictly required for Vif-mediated degradation of A3H, and that RNA and Vif are likely to bind this single-domain DNA cytosine deaminase on physically distinct surfaces. However, a subset of the results also indicated that the A3H degradation process may be affected by A3H protein structure, subcellular localization, and differences in the constellation of A3H interaction partners, suggesting additional factors may also influence the fate and functionality of this host-pathogen interaction.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  APOBEC3H; DNA cytosine deaminase; HIV-1 Vif; Subcellular localization; Vif-APOBEC interaction

Year:  2019        PMID: 31628948      PMCID: PMC6948013          DOI: 10.1016/j.jmb.2019.09.014

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  69 in total

1.  The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.

Authors:  Silvestro G Conticello; Reuben S Harris; Michael S Neuberger
Journal:  Curr Biol       Date:  2003-11-11       Impact factor: 10.834

2.  APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells.

Authors:  Jinhui Li; Yan Chen; Ming Li; Michael A Carpenter; Rebecca M McDougle; Elizabeth M Luengas; Patrick J Macdonald; Reuben S Harris; Joachim D Mueller
Journal:  J Mol Biol       Date:  2013-12-17       Impact factor: 5.469

3.  Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H.

Authors:  Ariana Harari; Marcel Ooms; Lubbertus C F Mulder; Viviana Simon
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

4.  HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.

Authors:  Kim Stopak; Carlos de Noronha; Wes Yonemoto; Warner C Greene
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

5.  The Antiviral and Cancer Genomic DNA Deaminase APOBEC3H Is Regulated by an RNA-Mediated Dimerization Mechanism.

Authors:  Nadine M Shaban; Ke Shi; Kate V Lauer; Michael A Carpenter; Christopher M Richards; Daniel Salamango; Jiayi Wang; Michael W Lopresti; Surajit Banerjee; Rena Levin-Klein; William L Brown; Hideki Aihara; Reuben S Harris
Journal:  Mol Cell       Date:  2017-12-28       Impact factor: 17.970

6.  Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation.

Authors:  Hendrik Huthoff; Michael H Malim
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

Review 7.  A conflict of interest: the evolutionary arms race between mammalian APOBEC3 and lentiviral Vif.

Authors:  Yusuke Nakano; Hirofumi Aso; Andrew Soper; Eri Yamada; Miyu Moriwaki; Guillermo Juarez-Fernandez; Yoshio Koyanagi; Kei Sato
Journal:  Retrovirology       Date:  2017-05-08       Impact factor: 4.602

8.  Structural Determinants of the APOBEC3G N-Terminal Domain for HIV-1 RNA Association.

Authors:  Hirofumi Fukuda; Songling Li; Luca Sardo; Jessica L Smith; Kazuo Yamashita; Anamaria D Sarca; Kotaro Shirakawa; Daron M Standley; Akifumi Takaori-Kondo; Taisuke Izumi
Journal:  Front Cell Infect Microbiol       Date:  2019-05-21       Impact factor: 5.293

9.  NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity.

Authors:  In-Ja L Byeon; Jinwoo Ahn; Mithun Mitra; Chang-Hyeock Byeon; Kamil Hercík; Jozef Hritz; Lisa M Charlton; Judith G Levin; Angela M Gronenborn
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis.

Authors:  Gabriel J Starrett; Elizabeth M Luengas; Jennifer L McCann; Diako Ebrahimi; Nuri A Temiz; Robin P Love; Yuqing Feng; Madison B Adolph; Linda Chelico; Emily K Law; Michael A Carpenter; Reuben S Harris
Journal:  Nat Commun       Date:  2016-09-21       Impact factor: 14.919

View more
  2 in total

Review 1.  Dual Functionality of HIV-1 Vif in APOBEC3 Counteraction and Cell Cycle Arrest.

Authors:  Daniel J Salamango; Reuben S Harris
Journal:  Front Microbiol       Date:  2021-01-12       Impact factor: 5.640

2.  Polymorphisms in Human APOBEC3H Differentially Regulate Ubiquitination and Antiviral Activity.

Authors:  Nicholas M Chesarino; Michael Emerman
Journal:  Viruses       Date:  2020-03-30       Impact factor: 5.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.